3-Injection Data*

shoe image

*Some patients may experience benefit with 3 injections given at weekly intervals; this benefit has been noted in studies reported in the literature in which patients treated with 3 injections were followed for 60 days.10

For osteoarthritis knee pain

3 for 3 efficacy


HYALGAN® has demonstrated 3 injection efficacy in 3 placebo controlled clinical trials.*8,30-31


Proven pain relief with 3 injections10,11


Pain relief at day 60:
HYALGAN® 3-injection regimen vs placebo

Hyalgan® 3-Injection regimen vs placebo line graph
Significantly decreased pain11

Adapted from Carrabba M et al. P<.05 vs saline control.

As measured using a 100-mm VAS.11

Study design

Six-month, double-blind, placebo- and arthrocentesis-controlled trial; patients (N=100) were randomized into 5 groups (saline-control weekly X 5, plus arthrocentesis at baseline; arthrocentesis weekly X 5; IA HYALGAN® 20 mg weekly X 1, plus arthrocentesis weekly X 5; IA HYALGAN® 20 mg weekly X 3, plus arthrocentesis at baseline and days 21 and 28; IA HYALGAN® 20 mg weekly X 5, plus arthrocentesis at baseline).11


For osteoarthritis knee pain

Proven again—pain relief with 3 injections10,12


Pain relief at day 60:
HYALGAN® 3-injection regimen vs placebo

Hyalgan® 3-Injection regimen vs placebo line graph
Significantly decreased pain12

Adapted from Bragantini A et al.

As measured using a 100-mm VAS.12

Study design

Placebo-controlled, single-blind parallel study (N=55) comparing 20 mg HYALGAN® weekly X 3, 40 mg HYALGAN® weekly X 3, and 2 mL saline weekly X 3.12


For osteoarthritis knee pain

Proven again—pain relief with 3 injections10,13


Pain relief at day 60:
HYALGAN® 3-injection regimen vs placebo

Hyalgan® 3-Injection regimen vs placebo bar graph
Significantly decreased pain13

Adapted from Grecomoro G et al.

§As measured using a 100-mm VAS.13

Study design

Randomized, placebo-controlled, double-blind study (N=34 patients; 40 joints) comparing 20 mg HYALGAN® weekly X 3 and placebo (phosphate buffer) weekly X 3.13

*Some patients may experience benefit with 3 injections given at weekly intervals; this benefit has been noted in studies reported in the literature in which patients treated with 3 injections were followed for 60 days.10

Important Safety Information for HYALGAN®

  • HYALGAN® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpha-rmacologic therapy, and to simple analgesics, eg, acetaminophen
  • HYALGAN® is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site
  • The effectiveness of a single treatment cycle of less than 3 injections has not been established
  • In the US clinical trial of 495 patients, the only adverse event showing statistical significance vs placebo was injection-site pain
  • Other adverse events included gastrointestinal complaints, headache, local ecchymosis and rash, local joint pain and swelling, and local pruritus. However, the incidence of these events was similar in the HYALGAN®-treated and placebo groups
  • In other clinical studies, the frequency and severity of adverse events occurring during repeat treatment cycles did not increase over that reported for a single treatment cycle

Click here for additional important information for HYALGAN®.